Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or by accessing the investors section of the company's website within 72 hours.
哈肯薩克,紐約 / ACCESSWIRE / 2024年12月5日 / champions oncology, Inc. (納斯達克:CSBR),一家提供端到端腫瘤解決方案的全球前臨床和臨床研究服務提供商,將於2024年12月11日星期三市場關閉後公佈截至2024年10月31日的第二季度財務和運營結果。公司將在當天下午4:30(美國東部時間)舉行電話會議,討論結果(下午1:30,太平洋時間)。如要參加會議,請撥打888-506-0062(國內)或973-528-0011(國際),並輸入訪問代碼710610。會議回放可通過撥打877-481-4010(國內)或919-882-2331(國際)並輸入密碼:51750,或者在公司網站的投資者部分訪問,72小時內可用。
About Champions Oncology, Inc.
關於Champions Oncology, Inc。
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit .
champions oncology是全球臨床前和臨床研究服務提供商,爲生物製藥組織提供端到端的腫瘤研發解決方案。作爲擁有最大、最全面的與臨床相關的患者來源異種移植(PDX)和原發性血液惡性腫瘤模型庫的公司,champions通過獨特的體內和體外平台提供創新的高質量數據。通過其大型先進生物分析平台組合、突破性數據平台和分析以及科學卓越,champions促進了世界範圍內臨床前和臨床腫瘤藥物發現與開發項目的進展。欲了解更多信息,請訪問。
SOURCE: Champions Oncology, Inc.
SOURCE:Champions Oncology,Inc。